Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
Authors:
- Matthias R. LemkeMLMatthias R. Lemke
- H. Michael BrechtHBH. Michael Brecht
- Juergen KoesterJKJuergen Koester
- Heinz ReichmannHRHeinz Reichmann
- 1 October 2006
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 248 (1-2) , 266-270
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pramipexole for bipolar II depression: a placebo-controlled proof of concept studyBiological Psychiatry, 2004
- Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar DepressionAmerican Journal of Psychiatry, 2004
- What contributes to quality of life in patients with Parkinson's disease?Journal of Neurology, Neurosurgery & Psychiatry, 2000
- Deutsche Version der Snaith-Hamilton-Pleasure-Scale (SHAPS-D)Fortschritte der Neurologie · Psychiatrie, 1998
- A survey of antidepressant drug use in Parkinson's diseaseNeurology, 1997
- Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's diseaseNeurology, 1997
- Evaluation of the Short Parkinsonʼs Evaluation ScaleClinical Neuropharmacology, 1997
- Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study GroupJAMA, 1997
- Anhedonia in Schizophrenic, Depressed, or Alcohol-Dependent Patients - Neurobiological CorrelatesPharmacopsychiatry, 1994
- ParkinsonismNeurology, 1967